CONSTANT LEVERAGE LONG - NOVO-NORDISK B | Real-time Euronext Paris 05:48:47 24/06/2024 pm IST | ||
| 12.86 EUR | -10.42% |
|
| Current month | +113.22% | ||
| 1 month | +87.34% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24/24/24 | 12.86 | -10.42% |
| 21/24/21 | 14.35 | -10.23% |
| 20/24/20 | 15.98 | +27.83% |
| 19/24/19 | 12.5 | +3.30% |
| 18/24/18 | 12.1 | -6.74% |
Real-time Euronext Paris
Last update June 24, 2024 at 05:48 pm IST
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| 5XNMB | |
| ISIN | NLBNPNL2JAB9 |
| Date issued | 11/10/2023 |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | - € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 49.86 € |
|---|---|
| Lowest since issue | 1.305 € |
| Spread | 0.41 € |
| Spread % | 3.17% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
987.9
DKK
Average target price
934.3
DKK
Spread / Average Target
-5.43%
- Stock Market
- Certificates
- 5XNMB Certificat
